Can continuous glucose monitoring lower mortality for patients in the ICU?
Managing blood sugar in the ICU is critical. Continuous glucose monitoring (CGM) tracks glucose levels in real time, unlike standard point-of-care (POC) fingerstick tests. A systematic review suggests CGM might lower the risk of death and severe hypoglycemia, but the evidence is not strong enough to be certain. Your doctor will weigh the potential benefits against the costs and practical challenges.
What the research says
A 2024 systematic review and meta-analysis combined results from 18 randomized trials involving over 2,000 ICU patients. It found that CGM was linked to a 39% lower relative risk of death (very low certainty evidence) and a 56% lower risk of hypoglycemia (very low certainty evidence) compared to POC testing 2. However, the authors rated the evidence as 'very uncertain' because the trials were small and had limitations 2. Other studies on glucose control in the ICU have shown mixed results. For example, a 2020 meta-analysis of 57 trials found that intensive glucose control (aiming for normal blood sugar) reduced mortality slightly but increased severe hypoglycemia 10. A 2017 trial in critically ill children found no benefit and possible harm from tight glucose control 11. These findings highlight that glucose management is complex and that CGM's role is still being studied.
What to ask your doctor
- What are the potential benefits and risks of using CGM for my condition in the ICU?
- How does CGM compare to standard fingerstick monitoring in terms of accuracy and preventing hypoglycemia?
- Are there any practical challenges or costs associated with using CGM in this hospital?
- What blood sugar targets are typically used in this ICU, and how are they adjusted?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.